GILD

Gilead Sciences, Inc. News Headlines

$88.9
*  
0.04
0.04%
Get GILD Alerts
*Delayed - data as of Jul. 11, 2014 13:35 ET  -  Find a broker to begin trading GILD now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    GILD Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Gilead Sciences To Present At Wells Fargo Conference; Webcast At 10:00 AM ET
6/17/2014 9:00:00 AM - RTT News

Achillion Pharmaceuticals (ACHN) Jumps: Stock Up 20.9% - Tale of the Tape
6/17/2014 8:51:00 AM - Zacks.com

Strength Seen in bluebird bio, Inc. (BLUE) as Stock Shoots up 32.08% - Tale of the Tape
6/17/2014 8:44:00 AM - Zacks.com

Maxim's $22 Price Target On Achillion Is Far From Realistic
6/17/2014 3:33:00 AM - Seeking Alpha

Actelion's Selexipag Meets Primary Endpoint - Analyst Blog
6/16/2014 6:15:00 PM - Zacks.com

Celgene's Vidaza Disappoints in Phase III Study - Analyst Blog
6/16/2014 6:10:00 PM - Zacks.com

OncoMed's OMP-18R5 On Clinical Hold, Shares Down - Analyst Blog
6/16/2014 5:22:00 PM - Zacks.com

Agios Presents Data on AG-221 - Analyst Blog
6/16/2014 5:21:00 PM - Zacks.com

Karyopharm Therapeutics Skyrockets on Drug Trial News - Analyst Blog
6/16/2014 5:10:00 PM - Zacks.com

Novo Nordisk's Victoza 3 mg Positive in Phase III - Analyst Blog
6/16/2014 4:45:00 PM - Zacks.com

Sanofi's Diabetes Portfolio in Focus at American Diabetes Association Sessions - Analyst Blog
6/16/2014 4:30:00 PM - Zacks.com

Integra LifeSciences, Premier Ink 3-Year Purchase Deal - Analyst Blog
6/16/2014 2:50:00 PM - Zacks.com

AbbVie Gets Priority Review from FDA for HCV Treatment - Analyst Blog
6/16/2014 1:50:00 PM - Zacks.com

Gilead's HCV Combination Therapy Data Looks Promising - Analyst Blog
6/16/2014 11:40:00 AM - Zacks.com

Market Consensus For Gilead's Q2 Revenue At $5.3B Is $0.5B Light
6/16/2014 10:05:00 AM - Seeking Alpha

What Falling Estimates & Price Mean for Rexahn Pharmaceuticals (RNN) - Tale of the Tape
6/16/2014 8:45:00 AM - Zacks.com

Sector Update: Shares Mixed Pre-Market; Gilead Lifts on Phase 3 Results for Hepatitis C Treatment
6/16/2014 8:28:36 AM - MT Newswires

Sector Update: Healthcare
6/16/2014 8:28:11 AM - MT Newswires

Gilead: Japan Phase 3 Trial For Ledipasvir/Sofosbuvir Combination Met Main Goal
6/16/2014 1:39:00 AM - RTT News

InterMune's A Strong Buy As Esbriet Finally Has The Data Physicians, Patients, And FDA Have Longed For
6/14/2014 5:00:00 AM - Seeking Alpha

Shire to Conduct Trials on Vyvanse on FDA's Request - Analyst Blog
6/13/2014 6:25:00 PM - Zacks.com

AstraZeneca Boosts Pipeline with $232 Million Synairgen Deal - Analyst Blog
6/13/2014 6:20:00 PM - Zacks.com

Relief for Nektar after AADPAC Voting - Analyst Blog
6/13/2014 6:10:00 PM - Zacks.com

Sanofi/ Regeneron Present Postive Data on Sarilumab - Analyst Blog
6/13/2014 4:50:00 PM - Zacks.com

J&J, ViiV Healthcare Tie Up for Single-Tablet HIV Treatment - Analyst Blog
6/13/2014 4:20:00 PM - Zacks.com